Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial

BACKGROUND: Risks to mother and fetus following Ebola virus infection are very high. Evaluation of safety and immunogenicity of non-replicating Ebola vaccine candidates is a priority for use in pregnant women. This is the protocol for a randomized, open-label, single-center phase 3 clinical trial of...

Descripción completa

Detalles Bibliográficos
Autores principales: Karita, Etienne, Nyombayire, Julien, Ingabire, Rosine, Mazzei, Amelia, Sharkey, Tyronza, Mukamuyango, Jeannine, Allen, Susan, Tichacek, Amanda, Parker, Rachel, Priddy, Frances, Sayinzoga, Felix, Nsanzimana, Sabin, Robinson, Cynthia, Katwere, Michael, Anumendem, Dickson, Leyssen, Maarten, Schaefer, Malinda, Wall, Kristin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207821/
https://www.ncbi.nlm.nih.gov/pubmed/35725488
http://dx.doi.org/10.1186/s13063-022-06360-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9207821/
https://www.ncbi.nlm.nih.gov/pubmed/35725488
http://dx.doi.org/10.1186/s13063-022-06360-3

Ejemplares similares